Pediatr. praxi. 2011;12(4):258-260

Current data about HPV vaccination

MUDr.Jiří Sláma, Ph.D.
Onkogynekologické centrum, Gynekologicko-porodnická klinika VFN a 1. LF UK, Praha

Prophylactic vaccination against human papillomaviruses is intended for primary prevention of cervical cancers. Currently, there are

two approved vaccines – bivalent vaccine Cervarix, which protects against HPV 16, 18 and due to cross-protection against HPV 31, 33,

45 and quadrivalent vaccine Silgard, which protects against HPV 6, 11, 16, 18 and against HPV 31 due to cross-protection. Clinical trials

showed high efficacy and safety of both vaccines. Mass vaccination of HPV „naive“ persons could prevent most of the cases of cervical

cancers and benign condylomas.

Keywords: HPV, cervical carcinoma, precancer lesion, vaccination

Published: September 2, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Sláma J. Current data about HPV vaccination. Pediatr. praxi. 2011;12(4):258-260.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12-19. Go to original source... Go to PubMed...
    2. Villa LL, Costa RL, Petta CA, et al. High sustained efficacy of a prophyllactic quadrivalent human papillomavirus types 6, 11, 16 and 18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006; 95: 1459-1466. Go to original source... Go to PubMed...
    3. Harper DM. Prophylactic human papillomavirus vaccines to prevent cervical cancer: review of the Phase II and III trials. Therapy 2008; 5: 313-324. Go to original source...
    4. Chlíbek R. Imunogenita vakcín proti lidskému papilomaviru. Vakcinologie 2008; 2: 145-153.
    5. Harper DM, Williams KB. Prophylactic HPV vaccines: current knowledge of impact on gynecologic premalignancies. Discov Med 2010; 10: 7-17. Go to PubMed...
    6. http://www.msdi.cz/content/patients/products/silgardspc.pdf.
    7. http://www.cervikalnikarcinom.cz/files/4030_SPC_Cervarix_A3_brezen_2011_K1.pdf.
    8. Einstein MH, Baron M, Levin MJ, et al. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccin 2009; 5: 705-719. Go to original source... Go to PubMed...
    9. Paavonen J, Naud P, Salmerón J, et al. Efficacy of human papillomavirus (HPV) -16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009; 374: 301-314. Go to original source... Go to PubMed...
    10. Castelsagué X, Schneider A, Kaufman AM, Bosch FX. HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives. Gynecol Oncol 2009; 115: S15-S23. Go to original source... Go to PubMed...
    11. Jenkins D. A review of cross-protection against oncogenic HPV by an HPV - 16/18 AS04-adjuvated cervical cancer vaccine: Importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention. Gynecol Oncol 2008; 110: 18-25. Go to original source... Go to PubMed...
    12. Brown DR, Kjaer SK, Sigurdsson K, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 2009; 199: 926-935. Go to original source... Go to PubMed...
    13. Tjalma W. Human papillomavirus type distribution in cervical neoplasia: result from two parallel epidemiological studies in women with high-grade intraepithelial cervical neoplasia and invasive cervical cancer in Europe. Poster 766, IPV 2010, Montreal, Canada, July 3-8, 2010.
    14. Giuliano AR. Waccination of males: Yes. Abstract CS 3-3, Eurogin 2011, Portugal, May 8-11, 2011.

    Return to the content


    Pediatrics for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.